India based Natco Pharma Ltd. and its US partner, Allergan, Plc, on 23 Dec 2015, announced the out-of-court settlement of the ongoing patent litigation in US courts with Celgene, an American biotechnology company, over generic Lenalidomide (Brand name- Revlimid).